CASP8 and ovarian cancer: This study’s findings suggest that Axitinib and SDC interact with the targeted and selected protein receptor (Caspase-8 protein) on breast and ovarian cancer through a variety of hydrogen, conventional, covalent, and pi alkyl bonding interactions.